ESR1 and breast carcinoma: The CDK4/6 inhibitor palbociclib can further be used in combination with anti-estrogens and this parallel inhibition of the cell cycle and the ERα-signaling is an efficient treatment strategy for certain subgroups of breast cancer patients6.